



**HAL**  
open science

# The hide-and-seek game of the oncogenic Epstein-Barr virus-encoded EBNA1 protein with the immune system: An RNA G-quadruplex tale

Van-Trang Dinh, Nadège Loaëc, Alicia Quillévéré, Ronan Le Sénéchal, Marc Keruzoré, Rodrigo Prado Martins, Anton Granzhan, Marc Blondel

## ► To cite this version:

Van-Trang Dinh, Nadège Loaëc, Alicia Quillévéré, Ronan Le Sénéchal, Marc Keruzoré, et al.. The hide-and-seeek game of the oncogenic Epstein-Barr virus-encoded EBNA1 protein with the immune system: An RNA G-quadruplex tale. *Biochimie*, 2023, 214 (Pt A), pp.57-68. 10.1016/j.biochi.2023.07.010 . hal-04186108

**HAL Id: hal-04186108**

<https://hal.inrae.fr/hal-04186108>

Submitted on 10 Nov 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

# The hide-and-see game of the oncogenic Epstein-Barr virus-encoded EBNA1 protein with the immune system: an RNA G-quadruplex tale

Van-Trang Dinh<sup>1</sup>, Nadège Loaëc<sup>1</sup>, Alicia Quillévéré<sup>1</sup>, Ronan Le Sénéchal<sup>1</sup>, Marc Keruzoré<sup>1</sup>, Rodrigo Prado Martins<sup>2</sup>, Anton Granzhan<sup>3</sup> and Marc Blondel<sup>1\*</sup>

<sup>1</sup> Univ Brest; Inserm UMR1078; Etablissement Français du Sang (EFS) Bretagne; CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, 22 avenue Camille Desmoulins, F-29200 Brest, France

<sup>2</sup> ISP, INRAE, Univ Tours, UMR1282, Tours, Nouzilly, France

<sup>3</sup> Chemistry and Modelling for the Biology of Cancer (CMBC), CNRS UMR9187, Inserm U1196, Institut Curie, Université Paris Saclay, F-91405 Orsay, France

\* To whom correspondence should be addressed. Tel: +33 (0)2 98 01 83 88; Email: [marc.blondel@univ-brest.fr](mailto:marc.blondel@univ-brest.fr)

## Abstract

The Epstein-Barr virus (EBV) has been known for almost 60 years as the first oncogenic virus described in human and, nowadays, is still one of the most efficient means for transforming and immortalizing human B-cells. EBV infects more than 95% of the human population worldwide, but most EBV infections are asymptomatic. Nevertheless, when EBV primary infection occurs during adolescence or young adulthood, it can lead to an acute infection known as infectious mononucleosis. After the primary infection, the virus persists lifelong in the memory B cells of the infected individuals. Under certain conditions the virus can cause several human cancers, that include lymphoproliferative disorders such as Burkitt and Hodgkin lymphomas and non-lymphoid malignancies such as 100% of nasopharyngeal carcinoma and 10% of gastric cancers. Each year, about 200,000 EBV-related cancers emerge, hence accounting for at least 1% of worldwide cancers. Like all the gammaherpesviruses, EBV has evolved a strategy to escape the host immune system. This strategy is mainly based on the tight control of the expression of its Epstein-Barr nuclear antigen-1 (EBNA1) protein, the EBV-encoded genome maintenance protein. Indeed, EBNA1 is essential for viral genome replication and maintenance but, at the same time, is also highly antigenic and T cells raised against EBNA1 exist in infected individuals. For this reason, EBNA1 is considered as the Achilles heel of EBV and the virus has seemingly evolved a strategy that employs host cell factors binding on RNA G-quadruplex (rG4) within EBNA1 mRNA to limit its expression to the minimal level required for function while minimizing immune recognition. This review recapitulates in an historical way the knowledge accumulated on EBNA1 immune evasion and discusses how this rG4-dependent mechanism can be exploited as a therapeutic target to unveil EBV-related cancers to the immune system.

## Introduction

1 Although first observed at the beginning of the 20<sup>th</sup> century [1], the Burkitt lymphoma (BL) was first  
2 described in 1958 as a prevalent lymphosarcoma affecting young children in sub-Saharan Africa [2]. It  
3 was then rapidly realized that the zone of incidence of BL coincided with the one of malaria, leading to  
4 the hypothesis that malaria could be responsible, or at least a cofactor for BL. In this context, Anthony  
5 Epstein and his student Yvonne Barr made the first observation, thanks to electron microscopy, of the  
6 so-called Epstein-Barr virus (EBV) in cultured lymphoblasts from Burkitt lymphoma ([3, 4]). A couple of  
7 years later, translocation and resulting activation of the *c-MYC* oncogene was detected in BL [5, 6].  
8 Altogether these observations have paved the way for the current model that EBV, *c-MYC* and malaria  
9 collaborate to cause BL (reviewed in [7]). Indeed, shortly after its discovery in 1964, the hypothesis that  
10 EBV may cause cancers has emerged, notably based on the observation that almost 100% of BL in  
11 tropical Africa were latently infected by the virus [8] and carry the viral genome as a clonal extra-  
12 chromosomal episome [9]. This way, EBV was the first oncogenic virus described in human and is still  
13 nowadays one of the most efficient means for transforming and immortalizing human B-cells. EBV  
14 infects more than 95% of the human population worldwide, but most EBV infections are asymptomatic  
15 even though, when EBV primary infection occurs during adolescence or young adulthood, it can lead to  
16 an acute infection known as infectious mononucleosis. After the primary infection, the virus persists  
17 lifelong in the memory B cells of the infected individuals. Under certain conditions the virus can cause  
18 several human cancers, that includes lymphoproliferative disorders such as Burkitt and Hodgkin  
19 lymphomas, non-lymphoid malignancies such as 100% of nasopharyngeal carcinoma, 10% of gastric  
20 cancers, rare T- and NK-cells lymphomas as well as leiomyosarcoma [10-12] and, potentially,  
21 gliomas [13]. EBV is therefore found in a variety of human cancers whose localisation mostly overlaps  
22 with the known tissue tropism of the virus for B and epithelial cells. According to some estimations, about  
23 200,000 EBV-related cancers emerge per year, hence accounting for at least 1% of cancer worldwide  
24 [14]. In addition, a link between EBV primo-infection and multiple sclerosis has been suspected for a  
25 long time and firmly confirmed recently [15]. For all these reasons, EBV became one of the most studied  
26 human viruses so far. As a latent virus, like all the gammaherpesviruses, EBV has evolved a strategy to  
27 escape the host immune system. This strategy is mainly based on the tight control of the expression of  
28 its Epstein-Barr nuclear antigen-1 (EBNA1) protein, the EBV-encoded genome maintenance protein of  
29 the virus [16]. Indeed, EBNA1 is considered as the Achilles heel of EBV due to the fact it is essential for  
30 viral genome replication and maintenance but, at the same time, it is also highly antigenic and T cells  
31 raised against EBNA1 exist in infected individuals [17-22]. This review aims at recapitulating the  
32 knowledge about the EBNA1-based immune evasion of EBV and how the discovered mechanisms can  
33 define original therapeutic targets to unveil EBV-related cancers to the immune system.

### EBNA1 is the Genome Maintenance Protein (GMP) of EBV

34 EBNA1 is a multifunctional EBV-encoded protein whose primary function is to ensure EBV genome  
35 replication and maintenance, hence being considered the genome maintenance protein (GMP) of the  
36 virus [23]. In addition, EBNA1 plays a role in transcriptional activation of the EBV latency genes in latent  
37 infection [24, 25]. EBNA1 is a multi-domain protein (**Figure 1**) that contains, from residue 90 to 328 in

1 its N-term part, a glycine alanine repeat (GAR) that consists of a stretch of single alanines separated by  
2 one, two or three glycines. This GAR domain is conserved across all EBV strains and plays a critical role  
3 in the ability of EBNA1, and thereby of EBV, to evade the immune system during the latent phase of  
4 viral infection (described in details later in this review). Importantly, a natural polymorphism in the length  
5 of GAR exists and the ability of GAR to allow immune evasion of EBNA1 is GAR-length-dependent: the  
6 longer GAR, the most efficient the immune evasion is. The GAR domain is flanked on each side by a  
7 glycine-arginine-rich (RGG) motif. RGG motifs (aka RGG boxes) are low complexity sequences that  
8 contain repetitions of the arginine-glycine-glycine tripeptide. RGG motifs can lead to intrinsically  
9 disordered regions [26] and have been involved in interactions with nucleic acids and various proteins  
10 [27]. The first RGG motif of EBNA1 is located from residue 33 to 64 whereas the second lies between  
11 residues 329 and 377 and both are responsible for EBNA1 association to host cell metaphase  
12 chromosomes, hence supporting EBV genome replication and maintenance [28-30]. The second RGG  
13 motif of EBNA1 is followed by a monopartite nuclear localization signal NLS (KRPRSPSS, residues 379  
14 to 386) and then by a C-terminal DNA-binding and dimerization domain (from residue 459 to 609), which  
15 is also responsible for the attachment of the viral genome to the cellular chromatin to ensure the viral  
16 replication [16, 31].

24 The function of EBNA1 in genome replication and maintenance also relies on its capacity to bind to  
25 multiple sites on the origin of DNA replication (OriP) of EBV genome. The EBV OriP contains two cis-  
26 acting components, a dyad symmetry (DS) element, and a family of repeats (FR) [32, 33]. The DS  
27 element is a repetition of four EBNA1 binding sites divided in two by a 9 bp sequence, it is responsible  
28 for DNA replication and it has also been shown to be sufficient for EBNA1-dependent EBV replication  
29 [31, 32, 34]. The FR element consists of 20 tandem copies of a 30 bp sequence containing a 18 bp  
30 palindromic element on which EBNA1 binds, followed by 12 bps corresponding to an AT-rich  
31 element [35]. This FR element is not directly involved in DNA replication but, the mitotic segregation of  
32 the EBV episome requires binding of EBNA1 to its multiple recognition sites in the FR element for  
33 ensuring efficient attachment to host cell chromosomes [31, 36].

40 In addition, thanks to a yeast-based two-hybrid screen, EBNA1 was shown to specifically interact also  
41 with a host cell nuclear protein, the so-called Epstein-Barr binding protein 2 (EBP2). This protein-protein  
42 interaction appears to be important for the role of EBNA1 in EBV episome stable segregation through  
43 association to host cell chromosomes in metaphase [31, 37, 38]. EBNA1 region that binds to EBP2 has  
44 been mapped to the second RGG motif of EBNA1 (residues 329 to 377) whose deletion prevents  
45 interaction of EBNA1 with EBP2 and consequently affects EBV genome maintenance [38]. This EBNA1-  
46 EBP2 proteins interaction has been furthermore reconstituted in the budding yeast *Saccharomyces*  
47 *cerevisiae*. This way, EBP2 was demonstrated to be crucial for the maintenance of an EBV FR element-  
48 containing plasmid maintenance [39-41]. EBNA1 is therefore a crucial protein for EBV DNA replication  
49 and episome maintenance, particularly in B cells which are actively dividing cells.

56 As stated above, EBNA1 is also implicated in transcriptional activation of the EBV latency genes in latent  
57 infection [24, 25]. The 65–83 N-terminal EBNA1 residues [42, 43] as well as the second RGG motif  
58 (residues 329 to 377) [44-46] are required for transcriptional activation. EBNA1 requires both of these

1 regions to activate transcription, as deletion of either one abrogates the transcriptional activation function  
2 of EBNA1 [43, 44]. Of note, a  $\Delta 61-83$  EBNA1 mutant was found to be fully active for replication and  
3 segregation functions, indicating that transcriptional activation is a distinct EBNA1 function, separable  
4 from its GMP role [43].  
5  
6  
7

### 8 **EBNA1 is the Achilles heel of EBV**

9

10 Like all the gamma herpesviruses, EBV is a latent virus that evades the host immune system. However,  
11 as said above, EBV possesses an Achilles heel: its virally-encoded genome maintenance protein  
12 EBNA1 (Epstein-Barr nuclear antigen 1). Indeed, being essential for replication and maintenance of the  
13 viral genome, EBNA1 is required for viral persistence but, at the same time, highly antigenic and T cells  
14 directed EBNA1 epitopes exist in nearly all EBV-infected individuals [17-22]. Hence, EBV evolved a  
15 mechanism by which EBNA1 limits the presentation of EBNA1-derived antigenic peptides. This ability  
16 of EBNA1 to evade the immune system has been rapidly attributed to its GAR domain which prevents  
17 EBNA1-derived antigenic peptides to be presented to the MHC class I pathway [47]. Importantly, this  
18 *in cis* effect of GAR is autonomous and transferable since, when fused to other proteins such as EBNA4,  
19 ovalbumin (OVA), or the herpes simplex virus thymidine-kinase, GAR also interfere with their antigenic  
20 presentation [47-50]. Of note, the study by Maria Masucci and collaborators represents a milestone  
21 since, not only it demonstrated the crucial role of GAR in the immune evasion of EBNA1, but it also  
22 represented a proof of principle that interfering with GAR-based immune evasion of EBNA1 may  
23 represent an intervention point to unveil EBV-infected cells, in particular tumoral cells from EBV-  
24 associated cancers, to the immune system [20, 47].  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 **A historical perspective on the role of GAR in EBNA1 immune evasion: the proteasome era** 37 **followed by the ribosome era**

38

39 At the time the role of GAR in immune evasion of EBNA1, and thus of EBV, was discovered, the main  
40 dogma was that most antigenic peptides for the MHC class I pathway comes from 26S proteasome-  
41 mediated degradation of full-length proteins (reviewed in [51]). In this context, several teams have  
42 observed that the GAR domain is able to efficiently inhibit *in cis* protein degradation by the 26S  
43 proteasome. This has been shown by observing that the fusion of GAR to several short half-life proteins,  
44 that include p53 and I $\kappa$ B $\alpha$ , interferes with their 26S proteasome-dependent degradation [52-54] and this  
45 effect has been shown to be GAR-length-dependent [53, 55, 56]. It was thus quite logical, on this ground,  
46 to infer that most of the capacity of GAR to inhibit antigen presentation was due to its ability to inhibit  
47 26S-dependent proteolysis (**Figure 2, left part**). However, at the same time, some important problems  
48 associated to this model of antigenic presentation, in particular regarding the kinetics of antigenic  
49 presentation by the MHC class I pathway, have started to emerge [57-59]. In line, as early as 1996,  
50 Jonathan Yewdell has proposed an alternative hypothesis in which the most important source of  
51 antigenic peptides would mainly originate from the so-called defective ribosomal products (DRiPs) [58,  
52 59]. DRiPs correspond to abortive byproducts of the translation process that include defective, misfolded  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 or prematurely terminated polypeptides. The first observation supporting this hypothesis is that most  
2 viral proteins are very stable, suggesting that the degradation of full-length proteins (the so-called  
3 “retirees”) by the proteasome and the consecutive presentation of derived antigenic peptides by the  
4 MHC class I would take long time, from hours to days, which is not consistent with the experimental  
5 observations that the kinetic of presentation of antigenic peptides by the MHC class I pathway following  
6 viral infection is rather rapid (from a few minutes to a few hours) and may happen even before the  
7 synthesis of mature full-length proteins. In addition, there is a tight correlation between the onset of  
8 protein expression and epitope display for most antigens, which represents a strong indication that  
9 antigen presentation is largely linked to translation and not to degradation of mature full-length proteins  
10 (retirees) [57, 60]. Indeed, from a number of T cell based-studies, it is clear that numerous antigenic  
11 peptides from multiple viruses are rapidly produced following infection [61]. The tight kinetic link between  
12 viral gene translation and antigenic peptides generation has been extended to the proteomic level using  
13 mass spectrometry, for the vaccinia virus [60] and recently for the influenza A virus (IAV) [62]. Hence,  
14 the idea that most viral antigenic peptides come from the degradation of full-length viral proteins did not  
15 seem anymore a viable hypothesis. Finally, the ribosome hypothesis was further supported by data  
16 showing that the inhibition of *de novo* protein synthesis rapidly reduces the antigenic presentation by  
17 MHC class I molecules [63, 64]. All these findings suggest that antigenic peptides have a main source  
18 from translation itself (**Figure 2, right part**), in particular from DRiPs [57, 65]. Hence, the model in which  
19 the ability of the GAR domain of EBNA1 to enable its immune evasion, and therefore immune evasion of  
20 EBV, comes from its capacity to inhibit own degradation by the 26S proteasome started to be fragilized.  
21 In addition, several studies have found that EBNA1 protein, with or without GAR, is a very stable protein  
22 [50, 52, 66] like most viral proteins, although its stability may be tissue-dependent [66]. Also, the steady-  
23 state level of EBNA1 protein was strongly increased in cells expressing a version of EBNA1 deleted for  
24 its GAR domain (EBNA1ΔGAR) as compared to cells expressing the wild-type EBNA1 (EBNA1wt), which  
25 was not expected when removing a domain that would inhibit proteasomal degradation [50, 53]. Finally,  
26 when expressing in the budding yeast *Saccharomyces cerevisiae* GAR domains of various lengths fused  
27 to destabilized versions of the green fluorescent protein (GFP), harboring N-end rule or ubiquitin fusion  
28 degradation signals, the length-dependent effect of the GAR domain on protein stability was confirmed.  
29 However, the steady-state level of the various GAR-GFP fusions was inversely correlated to their degree  
30 of stabilization: the longer the GAR domain, the more the reporter protein was stable, but the smaller its  
31 steady-state level, which appears quite counterintuitive [56]. Altogether, all these indirect data  
32 suggested that the ability of GAR to promote immune evasion was not linked to its ability to inhibit the  
33 26S proteasome-mediated proteolysis and, even if GAR is able to inhibit proteasomal degradation of  
34 unstable proteins to which it is fused, this effect is not operant in EBNA1 which is a stable protein.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

#### 54 **The ability of GAR to interfere with EBNA1 immune evasion is linked to its capacity to interfere** 55 ***in cis* with the translation of its own mRNA** 56

57 In a seminal study published in 2003, the use of *in vitro* expression systems and cell-based metabolic  
58 labeling led to the demonstration that the increase in EBNA1ΔGAR, as compared to EBNA1wt, was due  
59 to an increase in the rate of EBNA1 synthesis [50]. Not only this striking result explained all the previously  
60  
61  
62  
63  
64  
65

1 described results that did not fit with an effect of GAR on proteasomal degradation, but, more importantly,  
2 it was the starting point for other studies that unambiguously demonstrated that GAR does in fact inhibit  
3 *in cis* the translation of its own mRNA (EBNA1 mRNA) or of any messenger RNA (mRNA) to which it is  
4 fused, without affecting *in trans* the translation of other mRNA [48, 67]. This important demonstration  
5 was fully in line with the growing role of translation and of DRIPs in the genesis of antigenic peptides for  
6 the MHC class I pathway and readily explained the effect of GAR on immune evasion of EBNA1, and  
7 therefore of EBV [68]. These important results have then been confirmed [66] and converged to the  
8 model in which the endogenous presentation of EBNA1-derived antigenic peptides is dependent on the  
9 newly synthesized EBNA1 protein rather than on the long-lived stable EBNA1 protein, hence highlighting  
10 the inhibitory role of GAR on translation as the main mechanism explaining its inhibitory effect on antigen  
11 presentation (**Figure 2b, right part**). Importantly, the GAR-encoding sequence does not represent *per*  
12 *se* a hurdle to mRNA translation by the ribosome since the insertion of the *c-Myc* internal ribosome entry  
13 site (IRES) in the 5' untranslated transcribed region (UTR) of EBNA1 or GAR-OVA fusion-coding mRNA  
14 abolishes GAR-based inhibition of both translation and antigen presentation [48, 67]. This result also  
15 indicated that the GAR-inhibitory effect on translation requires cap-dependent translation initiation  
16 factors.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **Tools to monitor the GAR inhibitory effect on translation: setup of a yeast-based assay amenable** 28 **to high throughput drug and genetic screenings**

29  
30 Once the GAR inhibitory effect on translation firmly established, it rapidly appeared as a relevant  
31 intervention point to unveil EBV-infected cells, in particular tumor cells of cancers linked to EBV, to the  
32 immune system, hence the need for robust cell-based systems allowing both drug and genetic  
33 screenings. For various reasons, the budding yeast *Saccharomyces cerevisiae* has emerged as a  
34 relevant model system: notably, the study by the Masucci group already discussed above and based on  
35 the expression in yeast of destabilized GFP fused to GAR domains of various lengths indirectly  
36 suggested that the length-dependent inhibitory effect of GAR on translation is operant in yeast [56]. In  
37 addition, the budding yeast *S. cerevisiae* is an eukaryote as easy to handle as a prokaryote and is most  
38 certainly the model system for which the most molecular tools are available. Finally, for decades, yeast  
39 has been harnessed by biomedical research, notably on the Epstein-Barr virus itself (reviewed in [41])  
40 and on virus immune evasion [69], and widely used for modeling various pathophysiological  
41 mechanisms responsible for a large variety of human disorders [70, 71]. A number of these yeast-based  
42 models have been successfully used for performing large-scale pharmacological screening that aimed  
43 at identifying candidate drugs or chemical probes (for examples see [72] or [73]) as well as genetic  
44 screenings that focused on deciphering novel key factors involved in the considered diseases (for  
45 examples see [74] or [75]). Therefore, a yeast model for monitoring the GAR-based inhibition of the  
46 translation of its own mRNA *in cis* has been set up [76]. In this model (described in **Figure 3a**), the yeast  
47 protein Ade2 belonging to adenine biosynthesis pathway was used as a reporter protein since: (i) like  
48 EBNA1 it is a stable protein and (ii) a convenient colorimetric system allows to easily (without any  
49 treatment) determine its steady-state level in living yeast cells. Indeed, whereas yeast cells that express  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Ade2 at a functional level form white colonies, yeast cells that do not express Ade2 (for example cells  
2 deleted for the *ADE2* gene -termed *ade2Δ*-) readily form red colonies on rich YPD medium and any  
3 intermediate level of Ade2 leads to the formation of pink colonies whose color intensity is inversely  
4 proportional to the level of Ade2 expressed. Hence, this simple reporter system allows to easily monitor  
5 subtle changes in the level of Ade2. For this reason, and based on the fact that GAR-based inhibition of  
6 translation is probably operant in yeast, fusions of GAR domains of various lengths (21, 43 or 235 amino  
7 acids) to Ade2 were tested in yeast and led to the formal demonstration that GAR inhibits *in cis* and in a  
8 length-dependent manner the translation of its own mRNA in yeast, without any significant effect on  
9 mRNA level nor on protein stability (which was expected given that Ade2 is a very stable protein). Hence,  
10 the 43GAR-Ade2 fusion leads to pink yeasts, thereby allowing to easily monitor the effect of GAR and  
11 serving as the screening basis for identifying compounds or genes able to interfere with its *in cis*  
12 inhibitory effect on translation: modifiers that counteract the GAR effect on translation would lead to whiter  
13 yeast colonies, whereas those exacerbating the GAR effect would lead to redder yeast colonies. This  
14 yeast-based assay has first been used for drug screening (**Figure 3b, left part**) and led to the  
15 identification of doxorubicin as a compound specifically counteracting the inhibitory effect of GAR on the  
16 expression of GAR-Ade2. This effect was GAR-dependent since doxorubicin had no effect on the  
17 expression of Ade2. The yeast assay was then definitively validated when doxorubicin was not only  
18 shown to stimulate EBNA1 expression in a GAR-dependent manner in human cells, but also to overcome  
19 the GAR-dependent restriction of MHC class I antigen presentation [76]. These results also suggested  
20 that, should host cell factors involved in GAR-based translation inhibition exist, they would be functionally  
21 conserved from yeast to human. This conclusion was the ground for the use of the yeast-based assay  
22 to perform a genetic screening (**Figure 3b, right part**) that aimed at identifying those potential host  
23 factors. The same readout (changes in the pink color of the 43GAR-Ade2 yeast strain) was used and the  
24 effect of overexpressing every single yeast gene was thus tested and led to the identification of the yeast  
25 *NSR1* gene [75, 77] which encodes the Nsr1 protein, the yeast ortholog of the human nucleolin (NCL).  
26 When overexpressed in yeast, Nsr1 or NCL led to a darker color of the 43GAR-Ade2 yeast strain due to  
27 the exacerbation of the GAR-based inhibition of translation, whereas the 43GAR-Ade2 yeast strain  
28 deleted for the *NSR1* gene form white colonies that express a higher level of the 43GAR-Ade2 fusion  
29 protein. Similar results were obtained when overexpressing or downregulating human NCL in human  
30 cells expressing EBNA1 or GAR-OVA fusions [75]. Altogether these results have highlighted nucleolin  
31 (NCL) as the first identified host cell factor required for GAR-based inhibition of translation, the  
32 mechanism at the basis of EBNA1 immune evasion. The question that came next was the precise role  
33 of NCL in GAR-based inhibition of translation.

### 51 **Crucial role of RNA G-quadruplex (rG4) and of their interaction with NCL in GAR-based inhibition** 52 **of translation and of antigen presentation**

53 G-quadruplexes (G4) are non-canonical secondary structures that may assemble in guanine-rich DNA  
54 or RNA. G4 are formed by the stacking of at least two G-quartets which consist of a planar arrangement  
55 of four guanines connected by Hoogsteen hydrogen bonds and stabilized by a central cation, most  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 often K<sup>+</sup>. G4 have been involved in gene regulation where they can affect transcription, splicing or  
2 translation [78-82]. Importantly, the central regions of most gamma herpesviruses genome maintenance  
3 proteins are highly homologous in terms of nucleotide sequence and are purine enriched [83]. At about  
4 the time NCL was identified as the first host factor involved in GAR effect on translation, the ability of the  
5 GAR-encoding sequence of EBNA1 mRNA to form a cluster of up to thirteen RNA G-quadruplex (rG4)  
6 was demonstrated and the possibility that these rG4 could impede ribosome progression has been  
7 proposed [84]. In line, in the same study, it was shown that destabilization of these rG4 by antisense  
8 oligonucleotides enhances both EBNA1 translation and presentation of EBNA1-derived antigenic  
9 peptides. However, as stated above, the fact that driving the translation initiation of a GAR-OVA mRNA  
10 by the *c-Myc* internal ribosome entry site (IRES) abolishes GAR-based inhibition of both translation and  
11 antigen presentation suggests that the GAR-encoding sequence does not represent *per se* a hurdle to  
12 the ribosome progression [48, 67]. In addition, at a low concentration (less than 1  $\mu$ M), EBNA1 mRNA  
13 was translated *in vitro* as efficiently as the EBNA1 $\Delta$ GAR mRNA [10]. In line, GAR-based inhibition of  
14 translation is not operant in a yeast *nsr1 $\Delta$*  strain deleted for nucleolin [75, 77] also suggesting that the  
15 series of rG4 that may assemble in GAR-encoding RNA are not *per se* able to significantly impede  
16 ribosome progression. Importantly, human nucleolin (NCL) has long been known to interact with G-  
17 quadruplex [85, 86], hence opening the possibility that NCL interacts with rG4 of the EBNA1 mRNA and  
18 that this interaction is crucial for GAR-based inhibition of EBNA1 translation and antigenic peptides  
19 presentation. This potential NCL/rG4 of EBNA1 mRNA interaction has been evidenced using both RNA  
20 pulldown [75, 87] and an adaptation of the proximity ligation assay (PLA) for monitoring RNA/protein  
21 interactions [75, 88]. Following these various observations, the benchmark G4-ligand PhenDC3 was  
22 tested and shown to interfere with NCL binding to rG4 of EBNA1 mRNA, thereby relieving GAR-based  
23 inhibition of both translation and antigenic peptide presentation by the MHC class I [75]. This result has  
24 motivated the screening of a series of 20 cationic bis(acylhydrazone) derivatives and led to the  
25 identification of two original G4-ligands, PyDH2 and PhenDH2, more active and less cytotoxic than  
26 PhenDC3 and interfering with EBV immune evasion also by disrupting the interaction between NCL and  
27 rG4 of EBNA1 mRNA [89]. Of note, doxorubicin, the compound isolated in the yeast assay that models  
28 GAR-based inhibition of translation described above [76] was recently shown to be a G4-ligand [90, 91],  
29 thus giving a plausible explanation for its ability to interfere with EBNA1 immune evasion. Also, it has  
30 been recently observed that insertion of the *c-Myc* IRES to the 5' UTR of GAR-OVA RNA prevents the  
31 interaction between NCL and rG4 of the GAR-encoding RNA, thus readily explaining its ability to abolish  
32 GAR-based inhibition of both translation and antigen presentation [92]. In addition, this result further  
33 confirms the importance of the NCL/rG4 of EBNA1 mRNA interaction for EBNA1 immune evasion.

34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 Finally, the mRNA encoding LANA1, the genome maintenance protein of the Kaposi virus, another  
51 oncogenic herpesvirus that also evades the immune system, has been proposed to also form rG4 in a  
52 central region presenting sequence similarity with the one encoding GAR, readily suggesting rG4 could  
53 represent a common feature that may allow immune evasion of various stealthy oncoviruses [84, 93].  
54 The existence and the crucial role of the rG4 of LANA1 mRNA in immune evasion of the Kaposi virus  
55 have recently been shown [94, 95].  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## The C-terminal RGG motif of NCL is crucial for its role in GAR-based inhibition of both translation and antigen presentation

The importance of the various domains of NCL protein for GAR-based inhibition of translation has been tested. NCL is composed of three domains: (i) an N-terminal domain that contains acidic stretches; (ii) a central region that contains four tandem RNA recognition motifs (RRM1 to RRM4); and (iii) a C-terminal RGG motif. Most nucleolin homologues known to date share the same organization, with some variation in the number of RRMs. Hence, the yeast nucleolin Nsr1 contains only two RRMs but possesses the acidic N-terminal domain as well as the C-terminal RGG motif. Importantly, and in contrast to NCL in human, Nsr1 is not essential in yeast as *nsr1Δ* strains, although growing rather poorly, are viable [96]. In addition, human nucleolin NCL can complement the effect of the loss of yeast Nsr1 on GAR-based inhibition of translation in yeast [75, 77]. For these reasons, an approach combining the use of the yeast model for GAR-based inhibition of translation in which the *NSR1* gene has been deleted (*43GAR-ADE2 nsr1Δ* strain) and the expression of either Nsr1 or NCL, or of parts of them, has been exploited to determine which domain of nucleolin is involved in this process and has identified the C-terminal RGG motif of both yeast and human nucleolin. Then, this RGG motif has been shown to interact with the rG4 of EBNA1 mRNA, thus being essential for EBNA1 ability to self-limit its expression [97].

One or two methyl groups can be attached to the nitrogen atoms of arginine, a process termed arginine methylation. This post-translational modification is conducted by protein arginine methyltransferases (PRMTs) [98]. These enzymes catalyze the transfer of a methyl group from S-adenosylmethionine (SAM) to the guanidino nitrogen atoms of arginine. There are nine PRMTs in human that are divided into three groups: type I, type II and type III which differ in the pattern of arginine methylation catalyzed [99]. Arginine methylation occurs in a variety of protein motifs, but the RGG motifs are the most commonly reported [100, 101] and, in budding yeast, it is estimated that the majority of arginine methylation occurs in RGG motifs [102]. For these reasons, the potential role of PRMTs in GAR-based inhibition of translation and antigen presentation has been tested. Hence, using drug-based or siRNA-mediated inhibition of PRMTs, it has been shown that type I PRMTs are required for the crucial role of nucleolin in GAR-based inhibition of translation and antigen presentation [97]. Next, the role of methylation of the arginines of the RGG motif of both yeast and human nucleolins has been directly evaluated by changing the eight arginines of the RGG motif of Nsr1, or the ten arginines of the RGG motif of NCL, by either alanines (to prevent methylation), lysines (to prevent methylation while maintaining the positive charge), or phenylalanines as mimics of methylated arginines. Indeed, phenylalanine has been shown to mimic methylated arginine as it carries a bulky hydrophobic moiety [103, 104]. Changing arginines into alanine or lysine suppress the interaction of NCL and Nsr1 with rG4 of EBNA1 mRNA, and thereby GAR-based inhibition of translation, whereas replacement of arginines by phenylalanines maintains both these phenomena [97]. Altogether, these results indicate that methylation of the arginines of the C-terminal RGG motif of nucleolin is necessary for its interaction with rG4 of the GAR-encoding sequence of EBNA1 mRNA, an interaction which is required for GAR-based inhibition of translation and, as a consequence, for EBNA1 immune evasion. Following these observations, two possible models for the role of methylation of the arginines of the C-terminal RGG motif of nucleolin could be envisioned: either this methylation directly promotes the interaction of NCL with rG4 of EBNA1

1 mRNA, or this methylation may interfere with the ability of the RGG motif of nucleolin to interact, and  
2 thus to be sequestered, by some of its partners (that can be proteins, DNA or RNA). In favor of this  
3 second possibility is the recent observation that Scd6, a yeast protein involved in translation inhibition,  
4 is able to self-associate via its RGG motif and that this self-association prevents its ability to inhibit  
5 translation and is negatively regulated by arginine methylation catalyzed by Hmt1, the main yeast type  
6 I PRMT [26]. *In vitro* experiments based on arginine methylation of bacterially produced recombinant  
7 NCL, or on either methylated or non-methylated RGG peptides have shown that methylation of the  
8 arginines of the C-terminal RGG motif of NCL does not significantly change its ability to interact with rG4  
9 of EBNA1 mRNA [97]. Hence, it seems that the RGG motif of NCL may be trapped by an unknown  
10 partner, thereby preventing its interaction with rG4 of EBNA1 mRNA and, upon type I PRMTs-mediated  
11 arginine methylation, the RGG motif of NCL is released and thus free to interact with rG4 of EBNA1  
12 mRNA, hence leading to immune evasion of EBNA1 (**Figure 4, left part**). Of note, the unknown partner  
13 of the RGG motif of NCL could be L3, a ribosomal protein that has been shown to interact with the RGG  
14 motif of NCL [105].

15  
16  
17  
18  
19  
20  
21 Finally, all these results bring out an intriguing point regarding the role of NCL in GAR-based self-  
22 limitation of EBNA1 expression and antigenic presentation. Indeed, NCL has also been positively  
23 involved in EBV episome maintenance and transcription through a direct interaction with the EBNA1  
24 protein [106]. Hence, NCL appears to positively control both EBV episome maintenance and  
25 transcription on the one hand, and the self-limitation of the EBV GMP (EBNA1) expression on the other.  
26 As for EBV, one can consider it makes sense to have the same host cell protein regulating these two  
27 key aspects of EBV's latency. Indeed, if NCL level is low, then the maintenance and transcription of EBV  
28 episome should be compromised but, as a result of NCL role in GAR-based limitation of EBNA1  
29 expression, EBNA1 mRNA should be more efficiently translated, which may compensate for its reduced  
30 level and favour the maintenance of EBV genome. On the contrary, if NCL level is high, then EBV  
31 episome will be efficiently maintained and transcribed, hence leading to a high level of EBNA1 mRNA,  
32 but then the increased NCL could further downregulate its translation, thereby limiting the level of  
33 EBNA1 protein and therefore its detection by the immune system. Importantly, as stated above, the role  
34 of NCL in EBNA1 immune evasion involves its ability to interact with G4 structures present in EBNA1  
35 mRNA, whereas its role in episome maintenance and transcription involves its ability to interact with  
36 EBNA1's N-terminal 100 amino acids (hence upstream of the GAR domain of EBNA1 protein) [106].  
37 Therefore, targeting the NCL-EBNA1 mRNA interaction should specifically affect EBNA1 immune  
38 evasion.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 **Therapeutic perspectives: potential intervention points and therapeutic avenues**

52  
53 Based on the current model of GAR-based inhibition of both EBNA1 expression and antigen presentation,  
54 two intervention points may be envisioned to unveil EBV-infected cells, in particular tumor cells of EBV-  
55 related cancers, to the immune system: (i) the interaction between rG4 of EBNA1 mRNA and the C-  
56 terminal RGG motif of NCL, and (ii) type I PRMTs (**Figure 5**). Importantly, in both cases proof-of-  
57 principles exist as G4 ligands that interfere with the rG4/NCL interaction on the one hand, and drugs  
58  
59  
60  
61  
62  
63  
64  
65

1 targeting type I PRMTs on the other, interfere with the GAR-based inhibition of translation and antigen  
2 presentation [75, 89, 97]. Of note, for both these therapeutic avenues, selectivity may be an issue (as  
3 for most of the drugs). Indeed, type I PRMTs may appear as relatively non-specific therapeutic targets  
4 as their inhibition could, in principle, affect the methylation of many proteins, similar to what has been  
5 initially considered for drugs inhibiting protein kinases or phosphatases. Of note, this potential lack of  
6 specificity has not prevented the development to the clinics of a number of kinases inhibitors [107], in  
7 particular in the field of cancer, and several inhibitors of PRMTs are currently being evaluated in clinical  
8 trials. Also, since RGG motifs are the main substrates of PRMTs and as, in various cell-based assays,  
9 type I inhibitors did not exhibit significant toxicity at concentration ranges in which they significantly affect  
10 both GAR-based translation inhibition and the interaction between NCL and rG4 of EBNA1 mRNA, the  
11 lack of specificity may not be an issue that could preclude their potential further developments to the  
12 clinics [97]. As for G4 ligands, an inherent limitation in their development to the clinics may also be their  
13 potential lack of specificity given that, in addition to the numerous rG4, there are hundreds of thousands  
14 potential DNA G4 (dG4) that may form in the human genome. Importantly however, G4 in the RNA  
15 context are often in a dynamic equilibrium with other structural isoforms, and even low doses of G4  
16 ligands may have a profound impact on this equilibrium, preventing or leading to the recruitment of the  
17 corresponding structure-specific binding factors (nucleolin in the case of the rG4 of EBNA1 mRNA).  
18 Another important point is that, besides the G-quartets, which are the constant elements constitutive of  
19 G4, there are other structural characteristics which vary from one sequence to another: the loops and  
20 the flanking regions. These elements ensure that each G4 is, in principle, unique within the whole  
21 genome or transcriptome and, as such, could be exploited as key targets to gain specificity through, for  
22 instance, the coupling of complementary oligonucleotides to G4-ligands [108]. Hence, it is not excluded  
23 that some specificity toward particular G4, notably rG4, may be reached and various methods to assess  
24 G4 ligands specificity have been described [109, 110]. Finally, the combined use of G4-ligands and  
25 inhibitors of type I PRMTs may also help to solve the specificity issue by potentially allowing the use of  
26 much reduced doses of both types of drugs.

27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40 The citrullination of arginines of the RGG motif of NCL may also be involved in the GAR-based  
41 mechanism of inhibition of both EBNA1 translation and antigen presentation. Indeed, deamination, also  
42 called citrullination, is the process of conversion of arginine into citrulline through enzymatic activation  
43 of peptidyl arginine deiminases (PADIs), notably PADI4 (aka PAD4), the main peptidyl arginine  
44 deiminase in human, thus preventing their methylation by PRMTs [111, 112]. Citrullination of RGG motifs  
45 was observed in several RGG-containing proteins, including NCL [113]. Interestingly, it has been  
46 reported that EBV infection activates several PRMTs, especially PRMT1, the main type I PRMTS, and  
47 at the same time inactivates PADI4 [114]. Hence, a possibility exists that EBV infection, by activating  
48 PRMT1 as well as inactivating PADI4, activates arginine methylation of the NCL C-terminal RGG motif,  
49 thus promoting the interaction of this protein with the G4s of EBNA1 mRNA, leading to limitation of its  
50 translation, and therefore to the evasion of EBNA1/EBV from the immune system (**Figure 4**).

51  
52  
53  
54  
55  
56  
57 Importantly, in addition to the GAR-encoding mRNA sequence, the GAR peptide could also participate to  
58 the inhibition of its own expression. For example, the addition of antibodies directed against the GAR  
59 domain can enhance the translation of GAR-carrying mRNAs, which supports the idea that the nascent  
60

1 GAR polypeptides could participate to the translation inhibition of its own mRNA [48, 67]. In addition, the  
2 nascent GAR peptides have recently been shown to interact with the nascent polypeptide-associated  
3 complex alpha (NACA) and displace it from the ribosome [115]. Endogenous NACA, in addition to bind  
4 to the GAR peptides, also interacts with GAR mRNA sequence as well as with NCL in the cell nucleus,  
5 thus facilitating NCL-EBNA1 mRNA interaction, thereby favoring mRNA translation inhibition *in cis*.  
6 Importantly, siRNA-mediated silencing of NACA expression interferes with the interaction between NCL  
7 and the rG4 of GAR mRNA and thus on GAR-based inhibition of both translation and antigenic peptides  
8 production [115]. Also, as stated above, the EBNA1 protein itself contains two RGG motifs: one  
9 upstream and one downstream of the GAR domain, and it has been shown that EBNA1 could bind to its  
10 own mRNA through its two RGG motifs [116] and also that these two RGG motifs could bind to rG4  
11 [117]. Moreover, these RGG domains are encoded by G-rich sequences in the EBNA1 mRNA that also  
12 have potential to form G-quadruplexes. These observations open two non-mutually exclusive  
13 possibilities that would implicate the RGG domains of EBNA1 in the mechanism of regulation of its  
14 expression. Firstly, like NCL, the EBNA1 protein could bind to the rG4 of its own mRNA through its two  
15 RGG motifs, and thus participate in the inhibition of its translation. The other possibility would be that,  
16 like the GAR-encoding sequence, the EBNA1 mRNA sequences encoding the two RGG motifs of EBNA1  
17 would be capable of forming rG4 that may also recruit NCL and/or EBNA1 protein(s) and would therefore  
18 participate to the inhibition of EBNA1 translation as well as the production of EBNA1-derived antigenic  
19 peptides, leading thus to the immune evasion of EBNA1/EBV. Of note, in both cases, type I PRMTs and  
20 PADIs may play a regulatory role. Interestingly, NCL and EBNA1 proteins have been reported to interact  
21 [106], hence opening the possibility of a cooperative binding on rG4 of EBNA1 mRNA, and thereby of a  
22 cooperative inhibitory effect of these two proteins on EBNA1 mRNA translation. All these possibilities  
23 clearly deserve detailed investigations.

34 Importantly, in addition to its crucial role in EBV genome replication and maintenance and in the virus  
35 immune evasion, EBNA1 has also been linked to cell transformation and, if the mechanism underlying  
36 its oncogenic activity is still unclear [16], it may involve the c-Myc oncogene. Indeed, the E $\mu$ EBNA1 mice  
37 that express EBNA1 in their B-cells thanks to the immunoglobulin heavy chain intronic enhancer (E $\mu$ )  
38 develop and succumb to B-cell lymphoma [118]. Importantly, the B cell tumours of these mice are  
39 monoclonal and remarkably similar to those induced by transgenic c-Myc expression (E $\mu$ myc transgenic  
40 mice, [119, 120]). However, contrary to the characteristic translocations observed in the *c-MYC* locus  
41 which are linked to the deregulation of its expression, in B cells tumours arising from E $\mu$ EBNA1  
42 transgenic mice the murine *c-MYC* locus was intact with no 5' rearrangements detected whereas the  
43 expression of c-Myc is also deregulated [118]. Hence, EBNA1 is able to induce overexpression of the  
44 *c-MYC* oncogene and, as such, may participate to the oncogenicity of EBV. Interestingly, recently a  
45 direct link between EBNA1 and C-Myc expression was revealed with the identification of a unique  
46 mechanism involving the GAR domain of EBNA1 [121]. In this model, the *in cis* GAR-mediated mRNA  
47 translation suppression causes a translational stress that activates the E2F1 transcription factor  
48 expression *via* phosphoinositide-3-kinase- $\delta$ - (PI3K $\delta$ -) dependent signalling. This increase in the level of  
49 E2F1 causes the induction of c-Myc. In support of this model are the observations that drug-based or  
50 siRNA-mediated specific inhibition of PI3K $\delta$  abrogate EBNA1-dependent induction of both E2F1 and c-  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Myc. Hence, in addition to be the GMP of EBV and to play a central role in the ability of the virus to  
2 evade the immune system, EBNA1 participate to the oncogenicity of EBV. Interestingly, both  
3 oncogenicity and immune evasion of EBV depend on the GAR domain of EBNA1. For this reason,  
4 pharmacological means that would result in exacerbating the GAR inhibitory effect on translation, by  
5 further decreasing EBNA1 level, may also be of therapeutic value for EBV-related cancers.  
6

7  
8 Finally, beyond cancer, EBV, and more particularly EBNA1, have been involved in other diseases,  
9 notably multiple sclerosis (MS). Indeed, the long-time suspected link between EBV and MS has recently  
10 been firmly confirmed in a large-scale study in which the authors analysed serum EBV antibodies from  
11 individuals who developed MS among a cohort of more than 10 million young adults in a more than 20  
12 years follow-up, and the results indicated a 32-fold increase in the risk of developing MS after EBV  
13 infection [15]. In parallel, a role for EBNA1 in MS has been proposed, notably via molecular mimicry  
14 leading to the development of cross-reactive antibodies and T cells [122, 123]. In line, a vaccine against  
15 EBNA1 appears a relevant therapeutic option to treat EBV-related disorders, in particular EBV-related  
16 cancers and MS, and several experimental vaccines have been developed against EBV, including  
17 against EBNA1 [124-126]. Notably, vaccination against EBNA1 has been shown efficient in eliciting  
18 comprehensive CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses which can translate into protection against EBV  
19 antigen expressing lymphomas [125, 127].  
20  
21  
22  
23  
24  
25  
26  
27

## 28 **Concluding remark**

29  
30 Beyond the clear interest of all the studies on EBNA1 biological roles and immune evasion for defining  
31 intervention points and novel therapeutic avenues to treat EBV-related diseases, in particular EBV-  
32 related malignancies, they also represent another illustration that “viruses are the best cell biologists” in  
33 that their study quite often leads to seminal discovery in cell biology.  
34  
35  
36  
37  
38

## 39 **Acknowledgments**

40  
41 This work was supported by the following grant agencies: ‘La Ligue contre le cancer CSIRGO’ and  
42 ‘Fondation pour l’Avenir’ to MB, ‘Agence Nationale de la Recherche’ (ANR-17-CE07-0004-01, to AG),  
43 French Ministry of Higher Education, Research and Innovation (PhD fellowships to RLS), ‘La Ligue  
44 contre le cancer Bretagne’ and ‘Région Bretagne’ (PhD fellowship to VTD), INCa PLBIO (PLBIO16-  
45 225) to MB and ‘Fondation pour la Recherche Médicale’ (DCM20181039571) to MB.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References

1. Davies, J.N., et al., *Cancer in an African Community, 1897--1956. An Analysis of the Records of Mengo Hospital, Kampala, Uganda. I.* Br Med J, 1964. **1**(5378): p. 259-64.
2. Burkitt, D., *A sarcoma involving the jaws in African children.* Br J Surg, 1958. **46**(197): p. 218-23.
3. Epstein, M.A., B.G. Achong, and Y.M. Barr, *Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma.* Lancet, 1964. **1**(7335): p. 702-3.
4. Epstein, M.A. and Y.M. Barr, *Cultivation in Vitro of Human Lymphoblasts from Burkitt's Malignant Lymphoma.* Lancet, 1964. **1**(7327): p. 252-3.
5. Klein, G., *Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men.* Cell, 1983. **32**(2): p. 311-5.
6. Manolov, G. and Y. Manolova, *Marker band in one chromosome 14 from Burkitt lymphomas.* Nature, 1972. **237**(5349): p. 33-4.
7. Thorley-Lawson, D.A. and M.J. Allday, *The curious case of the tumour virus: 50 years of Burkitt's lymphoma.* Nat Rev Microbiol, 2008. **6**(12): p. 913-24.
8. Magrath, I., *The pathogenesis of Burkitt's lymphoma.* Adv Cancer Res, 1990. **55**: p. 133-270.
9. Lindahl, T., et al., *Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line.* J Mol Biol, 1976. **102**(3): p. 511-30.
10. Daskalogianni, C., et al., *Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.* J Pathol, 2015. **235**(2): p. 334-41.
11. Longnecker, R. and F. Neipel, *Introduction to the human gamma-herpesviruses, in Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, A. Arvin, et al., Editors. 2007: Cambridge.*
12. Rezk, S.A., X. Zhao, and L.M. Weiss, *Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update.* Hum Pathol, 2018. **79**: p. 18-41.
13. Akhtar, S., et al., *Epstein-Barr Virus in Gliomas: Cause, Association, or Artifact?* Front Oncol, 2018. **8**: p. 123.
14. Cohen, J.I., et al., *Epstein-Barr virus: an important vaccine target for cancer prevention.* Sci Transl Med, 2011. **3**(107): p. 107fs7.
15. Bjornevik, K., et al., *Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.* Science, 2022. **375**(6578): p. 296-301.
16. Wilson, J.B., et al., *EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers.* Cancers (Basel), 2018. **10**(4).
17. Blake, N., et al., *Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.* Immunity, 1997. **7**(6): p. 791-802.
18. Lee, S.P., et al., *CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1.* J Exp Med, 2004. **199**(10): p. 1409-20.
19. Leen, A., et al., *Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.* J Virol, 2001. **75**(18): p. 8649-59.
20. Munz, C., *Epstein-Barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target.* J Exp Med, 2004. **199**(10): p. 1301-4.
21. Munz, C., et al., *Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.* J Exp Med, 2000. **191**(10): p. 1649-60.
22. Voo, K.S., et al., *Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.* J Exp Med, 2004. **199**(4): p. 459-70.
23. Blake, N., *Immune evasion by gammaherpesvirus genome maintenance proteins.* J Gen Virol, 2010. **91**(Pt 4): p. 829-46.
24. Gahn, T.A. and B. Sugden, *An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene.* J Virol, 1995. **69**(4): p. 2633-6.
25. Sugden, B. and N. Warren, *A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection.* J Virol, 1989. **63**(6): p. 2644-9.
26. Poornima, G., et al., *RGG-motif self-association regulates eIF4G-binding translation repressor protein Scd6.* RNA Biol, 2019. **16**(9): p. 1215-1227.
27. Thandapani, P., et al., *Defining the RGG/RG motif.* Mol Cell, 2013. **50**(5): p. 613-23.
28. Kang, M.S. and E. Kieff, *Epstein-Barr virus latent genes.* Exp Mol Med, 2015. **47**(1): p. e131.
29. Mackey, D. and B. Sugden, *The linking regions of EBNA1 are essential for its support of replication and transcription.* Mol Cell Biol, 1999. **19**(5): p. 3349-59.
30. Sears, J., et al., *The amino terminus of Epstein-Barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes.* J Virol, 2004. **78**(21): p. 11487-505.
31. Frappier, L., *The Epstein-Barr Virus EBNA1 Protein.* Scientifica (Cairo), 2012. **2012**: p. 438204.
32. Gahn, T.A. and C.L. Schildkraut, *The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication.* Cell, 1989. **58**(3): p. 527-35.
33. Reisman, D., J. Yates, and B. Sugden, *A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components.* Mol Cell Biol, 1985. **5**(8): p. 1822-32.

34. Wysokenski, D.A. and J.L. Yates, *Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus*. J Virol, 1989. **63**(6): p. 2657-66.
35. Rawlins, D.R., et al., *Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region*. Cell, 1985. **42**(3): p. 859-68.
36. Hodin, T.L., T. Najrana, and J.L. Yates, *Efficient replication of Epstein-Barr virus-derived plasmids requires tethering by EBNA1 to host chromosomes*. J Virol, 2013. **87**(23): p. 13020-8.
37. Nayyar, V.K., K. Shire, and L. Frappier, *Mitotic chromosome interactions of Epstein-Barr nuclear antigen 1 (EBNA1) and human EBNA1-binding protein 2 (EBP2)*. J Cell Sci, 2009. **122**(Pt 23): p. 4341-50.
38. Shire, K., et al., *EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance*. J Virol, 1999. **73**(4): p. 2587-95.
39. Kapoor, P. and L. Frappier, *EBNA1 partitions Epstein-Barr virus plasmids in yeast cells by attaching to human EBNA1-binding protein 2 on mitotic chromosomes*. J Virol, 2003. **77**(12): p. 6946-56.
40. Kapoor, P., K. Shire, and L. Frappier, *Reconstitution of Epstein-Barr virus-based plasmid partitioning in budding yeast*. EMBO J, 2001. **20**(1-2): p. 222-30.
41. Lista, M.J., et al., *The long-lasting love affair between the budding yeast Saccharomyces cerevisiae and the Epstein-Barr virus*. Biotechnol J, 2015. **10**(11): p. 1670-81.
42. Kennedy, G. and B. Sugden, *EBNA-1, a bifunctional transcriptional activator*. Mol Cell Biol, 2003. **23**(19): p. 6901-8.
43. Wu, H., P. Kapoor, and L. Frappier, *Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1*. J Virol, 2002. **76**(5): p. 2480-90.
44. Ceccarelli, D.F. and L. Frappier, *Functional analyses of the EBNA1 origin DNA binding protein of Epstein-Barr virus*. J Virol, 2000. **74**(11): p. 4939-48.
45. Van Scoy, S., et al., *Human p32: a coactivator for Epstein-Barr virus nuclear antigen-1-mediated transcriptional activation and possible role in viral latent cycle DNA replication*. Virology, 2000. **275**(1): p. 145-57.
46. Wang, Y., et al., *P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus*. Virology, 1997. **236**(1): p. 18-29.
47. Levitskaya, J., et al., *Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1*. Nature, 1995. **375**(6533): p. 685-8.
48. Apcher, S., et al., *Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation*. PLoS Pathog, 2010. **6**(10): p. e1001151.
49. Ossevoort, M., et al., *Characterization of an immuno 'stealth' derivative of the herpes simplex virus thymidine-kinase gene*. Cancer Gene Ther, 2006. **13**(6): p. 584-91.
50. Yin, Y., B. Manoury, and R. Fahraeus, *Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1*. Science, 2003. **301**(5638): p. 1371-4.
51. Rock, K.L. and A.L. Goldberg, *Degradation of cell proteins and the generation of MHC class I-presented peptides*. Annu Rev Immunol, 1999. **17**: p. 739-79.
52. Daskalogianni, C., et al., *Gly-Ala repeats induce position- and substrate-specific regulation of 26 S proteasome-dependent partial processing*. J Biol Chem, 2008. **283**(44): p. 30090-100.
53. Levitskaya, J., et al., *Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1*. Proc Natl Acad Sci U S A, 1997. **94**(23): p. 12616-21.
54. Sharipo, A., et al., *A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis*. Nat Med, 1998. **4**(8): p. 939-44.
55. Dantuma, N.P., et al., *Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal*. Proc Natl Acad Sci U S A, 2000. **97**(15): p. 8381-5.
56. Heessen, S., et al., *Inhibition of ubiquitin/proteasome-dependent proteolysis in Saccharomyces cerevisiae by a Gly-Ala repeat*. FEBS Lett, 2003. **555**(2): p. 397-404.
57. Yewdell, J.W., *DRiPs solidify: progress in understanding endogenous MHC class I antigen processing*. Trends Immunol, 2011. **32**(11): p. 548-58.
58. Yewdell, J.W., L.C. Anton, and J.R. Bennink, *Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol, 1996. 157(5): p. 1823-6.*
59. Yewdell, J.W. and C.V. Nicchitta, *The DRiP hypothesis decennial: support, controversy, refinement and extension*. Trends Immunol, 2006. **27**(8): p. 368-73.
60. Croft, N.P., et al., *Kinetics of antigen expression and epitope presentation during virus infection*. PLoS Pathog, 2013. **9**(1): p. e1003129.
61. Anton, L.C. and J.W. Yewdell, *Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors*. J Leukoc Biol, 2014. **95**(4): p. 551-62.
62. Wu, T., et al., *Quantification of epitope abundance reveals the effect of direct and cross-presentation on influenza CTL responses*. Nat Commun, 2019. **10**(1): p. 2846.
63. Dolan, B.P., et al., *Distinct pathways generate peptides from defective ribosomal products for CD8+ T cell immunosurveillance*. J Immunol, 2011. **186**(4): p. 2065-72.



64. Khan, S., et al., *Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein*. J Immunol, 2001. **167**(9): p. 4801-4.
65. Yewdell, J.W. and J. Holly, *DRiPs get molecular*. Curr Opin Immunol, 2020. **64**: p. 130-136.
66. Tellam, J., et al., *Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1*. J Exp Med, 2004. **199**(10): p. 1421-31.
67. Apcher, S., et al., *mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1*. J Virol, 2009. **83**(3): p. 1289-98.
68. Fahraeus, R., *Do peptides control their own birth and death?* Nat Rev Mol Cell Biol, 2005. **6**(3): p. 263-7.
69. Angrand, G., et al., *Sneaking Out for Happy Hour: Yeast-Based Approaches to Explore and Modulate Immune Response and Immune Evasion*. Genes (Basel), 2019. **10**(9).
70. Bach, S., P. Colas, and M. Blondel, *[Budding yeast, a model and a tool... also for biomedical research]*. Med Sci (Paris), 2020. **36**(5): p. 504-514.
71. Kachroo, A.H., et al., *Humanized yeast to model human biology, disease and evolution*. Dis Model Mech, 2022. **15**(6).
72. Bach, S., et al., *Isolation of drugs active against mammalian prions using a yeast-based screening assay*. Nat Biotechnol, 2003. **21**(9): p. 1075-81.
73. Couplan, E., et al., *A yeast-based assay identifies drugs active against human mitochondrial disorders*. Proc Natl Acad Sci U S A, 2011. **108**(29): p. 11989-94.
74. Giorgini, F., et al., *A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease*. Nat Genet, 2005. **37**(5): p. 526-31.
75. Lista, M.J., et al., *Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA*. Nat Commun, 2017. **8**: p. 16043.
76. Voisset, C., et al., *A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus*. Dis Model Mech, 2014. **7**(4): p. 435-44.
77. Lista, M.J., et al., *A yeast model for the mechanism of the Epstein-Barr virus immune evasion identifies a new therapeutic target to interfere with the virus stealthiness*. Microb Cell, 2017. **4**(9): p. 305-307.
78. Beaudoin, J.D. and J.P. Perreault, *5'-UTR G-quadruplex structures acting as translational repressors*. Nucleic Acids Res, 2010. **38**(20): p. 7022-36.
79. Didiot, M.C., et al., *The G-quartet containing FMRP binding site in FMR1 mRNA is a potent exonic splicing enhancer*. Nucleic Acids Res, 2008. **36**(15): p. 4902-12.
80. Gomez, D., et al., *Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing*. Nucleic Acids Res, 2004. **32**(1): p. 371-9.
81. Marcel, V., et al., *G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms*. Carcinogenesis, 2011. **32**(3): p. 271-8.
82. Siddiqui-Jain, A., et al., *Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription*. Proc Natl Acad Sci U S A, 2002. **99**(18): p. 11593-8.
83. Cristillo, A.D., et al., *Double-stranded RNA as a not-self alarm signal: to evade, most viruses purine-load their RNAs, but some (HTLV-1, Epstein-Barr) pyrimidine-load*. J Theor Biol, 2001. **208**(4): p. 475-91.
84. Murat, P., et al., *G-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation*. Nat Chem Biol, 2014. **10**(5): p. 358-64.
85. Dempsey, L.A., et al., *G4 DNA binding by LR1 and its subunits, nucleolin and hnRNP D, A role for G-G pairing in immunoglobulin switch recombination*. J Biol Chem, 1999. **274**(2): p. 1066-71.
86. Hanakahi, L.A., H. Sun, and N. Maizels, *High affinity interactions of nucleolin with G-G-paired rDNA*. J Biol Chem, 1999. **274**(22): p. 15908-12.
87. von Hacht, A., et al., *Identification and characterization of RNA guanine-quadruplex binding proteins*. Nucleic Acids Res, 2014. **42**(10): p. 6630-44.
88. Prado Martins, R., et al., *In Cellulo Protein-mRNA Interaction Assay to Determine the Action of G-Quadruplex-Binding Molecules*. Molecules, 2018. **23**(12).
89. Reznichenko, O., et al., *Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA*. Eur J Med Chem, 2019. **178**: p. 13-29.
90. Manet, I., et al., *Affinity of the anthracycline antitumor drugs Doxorubicin and Sabarubicin for human telomeric G-quadruplex structures*. Phys Chem Chem Phys, 2011. **13**(2): p. 540-51.
91. Scaglioni, L., et al., *Nemorubicin and doxorubicin bind the G-quadruplex sequences of the human telomeres and of the c-MYC promoter element Pu22*. Biochim Biophys Acta, 2016. **1860**(6): p. 1129-38.
92. Martins, R.P., et al., *Nuclear processing of nascent transcripts determines synthesis of full-length proteins and antigenic peptides*. Nucleic Acids Res, 2019. **47**(6): p. 3086-3100.
93. Murat, P. and J. Tellam, *Effects of messenger RNA structure and other translational control mechanisms on major histocompatibility complex-I mediated antigen presentation*. Wiley Interdiscip Rev RNA, 2015. **6**(2): p. 157-71.
94. Dabral, P., et al., *LANA and hnRNP A1 Regulate the Translation of LANA mRNA through G-Quadruplexes*. J Virol, 2020. **94**(3).
95. Zheng, A.J., et al., *The different activities of RNA G-quadruplex structures are controlled by flanking sequences*. Life Sci Alliance, 2022. **5**(2).
96. Lee, W.C., Z.X. Xue, and T. Melese, *The NSR1 gene encodes a protein that specifically binds nuclear localization sequences and has two RNA recognition motifs*. J Cell Biol, 1991. **113**(1): p. 1-12.

97. Angrand, G., et al., *Type I arginine methyltransferases are intervention points to unveil the oncogenic Epstein-Barr virus to the immune system*. *Nucleic Acids Res*, 2022. **50**(20): p. 11799-11819.
98. Wu, Q., et al., *Protein arginine methylation: from enigmatic functions to therapeutic targeting*. *Nat Rev Drug Discov*, 2021. **20**(7): p. 509-530.
99. Blanc, R.S. and S. Richard, *Arginine Methylation: The Coming of Age*. *Mol Cell*, 2017. **65**(1): p. 8-24.
100. Hamey, J.J., R.J. Separovich, and M.R. Wilkins, *MT-MAMS: Protein Methyltransferase Motif Analysis by Mass Spectrometry*. *J Proteome Res*, 2018. **17**(10): p. 3485-3491.
101. Lorton, B.M. and D. Shechter, *Cellular consequences of arginine methylation*. *Cell Mol Life Sci*, 2019. **76**(15): p. 2933-2956.
102. Yagoub, D., et al., *Yeast proteins Gar1p, Nop1p, Npl3p, Nsr1p, and Rps2p are natively methylated and are substrates of the arginine methyltransferase Hmt1p*. *Proteomics*, 2015. **15**(18): p. 3209-18.
103. Campbell, M., et al., *Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen*. *J Biol Chem*, 2012. **287**(8): p. 5806-18.
104. Mostaqul Huq, M.D., et al., *Suppression of receptor interacting protein 140 repressive activity by protein arginine methylation*. *EMBO J*, 2006. **25**(21): p. 5094-104.
105. Bouvet, P., et al., *Nucleolin interacts with several ribosomal proteins through its RGG domain*. *J Biol Chem*, 1998. **273**(30): p. 19025-9.
106. Chen, Y.L., et al., *Nucleolin is important for Epstein-Barr virus nuclear antigen 1-mediated episome binding, maintenance, and transcription*. *Proc Natl Acad Sci U S A*, 2014. **111**(1): p. 243-8.
107. Cohen, P., D. Cross, and P.A. Janne, *Kinase drug discovery 20 years after imatinib: progress and future directions*. *Nat Rev Drug Discov*, 2021. **20**(7): p. 551-569.
108. Cadoni, E., et al., *Beyond small molecules: targeting G-quadruplex structures with oligonucleotides and their analogues*. *Nucleic Acids Res*, 2021. **49**(12): p. 6638-6659.
109. Halder, K. and S. Chowdhury, *Quadruplex-coupled kinetics distinguishes ligand binding between G4 DNA motifs*. *Biochemistry*, 2007. **46**(51): p. 14762-70.
110. Scalabrín, M., et al., *Selective Recognition of a Single HIV-1 G-Quadruplex by Ultrafast Small-Molecule Screening*. *Anal Chem*, 2021. **93**(46): p. 15243-15252.
111. Cuthbert, G.L., et al., *Histone deimination antagonizes arginine methylation*. *Cell*, 2004. **118**(5): p. 545-53.
112. Wang, Y., et al., *Human PAD4 regulates histone arginine methylation levels via demethylation*. *Science*, 2004. **306**(5694): p. 279-83.
113. Tanikawa, C., et al., *Citrullination of RGG Motifs in FET Proteins by PAD4 Regulates Protein Aggregation and ALS Susceptibility*. *Cell Rep*, 2018. **22**(6): p. 1473-1483.
114. Leonard, S., et al., *Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkin's Lymphoma*. *Pathogens*, 2012. **1**(1): p. 52-64.
115. Zheng, A.J.L., et al., *The nascent polypeptide-associated complex (NAC) controls translation initiation in cis by recruiting nucleolin to the encoding mRNA*. *Nucleic Acids Res*, 2022. **50**(17): p. 10110-10122.
116. Norseen, J., et al., *RNA-dependent recruitment of the origin recognition complex*. *EMBO J*, 2008. **27**(22): p. 3024-35.
117. Norseen, J., F.B. Johnson, and P.M. Lieberman, *Role for G-quadruplex RNA binding by Epstein-Barr virus nuclear antigen 1 in DNA replication and metaphase chromosome attachment*. *J Virol*, 2009. **83**(20): p. 10336-46.
118. Wilson, J.B., J.L. Bell, and A.J. Levine, *Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice*. *EMBO J*, 1996. **15**(12): p. 3117-26.
119. Adams, J.M. and S. Cory, *Myc oncogene activation in B and T lymphoid tumours*. *Proc R Soc Lond B Biol Sci*, 1985. **226**(1242): p. 59-72.
120. Adams, J.M., et al., *The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice*. *Nature*, 1985. **318**(6046): p. 533-8.
121. Gnanasundram, S.V., et al., *PI3Kdelta activates E2F1 synthesis in response to mRNA translation stress*. *Nat Commun*, 2017. **8**(1): p. 2103.
122. Lanz, T.V., et al., *Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM*. *Nature*, 2022. **603**(7900): p. 321-327.
123. Soldan, S.S. and P.M. Lieberman, *Epstein-Barr virus and multiple sclerosis*. *Nat Rev Microbiol*, 2023. **21**(1): p. 51-64.
124. Cui, X. and C.M. Snapper, *Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases*. *Front Immunol*, 2021. **12**: p. 734471.
125. Ruhl, J., C.S. Leung, and C. Munz, *Vaccination against the Epstein-Barr virus*. *Cell Mol Life Sci*, 2020. **77**(21): p. 4315-4324.
126. Zhong, L., et al., *Urgency and necessity of Epstein-Barr virus prophylactic vaccines*. *NPJ Vaccines*, 2022. **7**(1): p. 159.
127. Ruhl, J., et al., *Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas*. *J Clin Invest*, 2019. **129**(5): p. 2071-2087.

## Figure Legends

### Figure 1: Schematic representation of the EBV-encoded EBNA1 protein highlighting the essential role of the GAR domain in immune evasion of the virus

The first 32 amino acids of EBNA1 full length are not associated to a particular function. The two RGG motifs (Arginine-Glycine-Glycine) are highlighted in gold (from amino acids 33 to 64 and 329 to 377), the GAR domain (Glycine-Alanine repeat) is shown in orange (from amino acids 90 to 328), the nuclear localization signal (NLS) is located between amino acids 378 and 386 and colored in black. The DNA-binding and dimerization domain (amino acids 459 to 609) is colored in purple. As EBNA1 full length, EBNA1ΔGAR is able to fulfill its essential functions for EBV genome replication and maintenance.

### Figure 2: The proteasome and the ribosome era parallel with the two consecutive models for EBNA1 immune evasion

On the left (**Proteasome era**) is represented the former model in which processing of the full-length EBNA1 protein by the 26S proteasome would be the main source of EBNA1-derived antigenic peptide. On this ground, the ability of GAR to inhibit *in cis* 26S proteasome-mediated proteolysis gave a plausible explanation for its role in immune evasion of EBNA1.

On the right (**Ribosome era**) is represented the current model in which most of antigenic peptides would originate from byproducts of the translation (the so-called defective ribosomal products -DRIPs-) of EBNA1 mRNA. Hence, in this model, the ability of GAR to limit *in cis* the translation of its own mRNA fully explains its inhibitory effect on antigen presentation.

### Figure 3: Rationale of the yeast-based assay for GAR-based inhibition of translation and use for both drug and genetic screenings

**a.** Rationale of the use of the Ade2 reporter protein in yeast. When Ade2 is expressed at a functional level yeast cells are white. When not expressed (*ade2Δ* cells), yeast cells are red. Any intermediate level of Ade2 leads to pink colonies whose colour intensity is inversely proportional to the level of Ade2 expression. This allows to easily monitor the GAR-inhibitory effect on translation in yeast.

**b.** Examples of use of the Ade2 reporter system for drug screening (left panel) aiming at identifying compounds that counteract the *in cis* inhibitory effect of GAR on translation, or genetic screening (right panel) to identify host genes involved in GAR-based inhibition of translation.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


**Figure 4: Model for the role of NCL and of the arginine methylation and citrullination of its C-terminal RGG motif in EBNA1 immune evasion**

In this model on the left, NCL would be trapped by an unknown factor (Protein X) which interacts with the unmethylated C-terminal RGG motif of NCL. Upon type I PRMTs-mediated methylation of the arginines of this RGG motif, the NCL/Protein X complex would be dissociated. Hence, the RGG motif of NCL would now be available to interact with the RNA G-quadruplexes (rG4) of EBNA1 mRNA, which is required for GAR-based limitation of translation, a phenomenon at the basis of EBNA1 immune evasion.


Citrullination (on the right), by preventing arginine methylation, would interfere with type I PRMTs-mediated methylation of the C-terminal RGG motif of NCL, hence interfering with GAR-based inhibition of translation and presentation of EBNA1-derived antigenic peptides.

**Figure 5: Possible intervention points to unveil EBNA1 to the immune system.**

Based on the model presented in **Figure 4**, at least two intervention points could be exploited to unveil EBV-infected cells (in particular tumour cells of EBV-related cancers) to the immune system: G4 ligands such as PhenDC3 that interfere with the binding of NCL on rG4 of EBNA1 mRNA (left) and compounds inhibiting type I PRMTs (right). By distinct modes of action, both types of drugs interfere with the binding of NCL on rG4 of EBNA1 mRNA, and thereby with the ability of GAR to self-limit the translation of its own mRNA. This, in turn, relieves the limitation of the production of EBNA1-derived antigenic peptides, ultimately interfering with immune evasion of EBNA1 and thus of EBV.



**EBV infection**







Figure 4

